scholarly journals A rare presentation of an ACTH‐producing high‐grade large cell neuroendocrine carcinoma with Cushing’s syndrome

2021 ◽  
Vol 9 (12) ◽  
Author(s):  
Francis Essien ◽  
Christine Persaud ◽  
David Dado ◽  
Rina Eden ◽  
Joshua Tate ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Cushing’S Syndrome ◽  
Large Cell ◽  
Cushing's Syndrome ◽  
Large Cell Neuroendocrine Carcinoma ◽  
High Grade ◽  
Rare Presentation

scholarly journals A rare presentation of an ACTH-producing high grade large cell neuroendocrine carcinoma with Cushing's syndrome

2021 ◽  
Author(s):  
Francis Essien ◽  
Christine Persaud ◽  
David Dado ◽  
Joshua Tate ◽  
George Shahin
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Rare Case ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
World Health ◽  
High Grade ◽  
Rare Tumor ◽  
Rare Presentation ◽  
The World ◽  
Health Organization

Large cell neuroendocrine carcinoma (LCNEC) was first proposed by Travis et al. in 1991 and subsequently classified as high grade neuroendocrine carcinoma (HGNEC) by the world health organization. It is a rare tumor with unclear clinicopathologic features. Herein, we describe a rare case of LCNEC with a unique Cushing’s presentation.

scholarly journals Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature

2013 ◽  
Vol 8 ◽  
Author(s):  
Yasuhiro Sakai ◽  
Takashi Yamasaki ◽  
Yoshito Kusakabe ◽  
Daisuke Kasai ◽  
Yoshikazu Kotani ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Neuroendocrine Carcinoma ◽  
Growth Factor Receptor ◽  
Large Cell ◽  
Kinase Domain ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Tyrosine Kinase Domain ◽  
High Grade ◽  
Epidermal Growth ◽  
L858r Mutation

Purpose: A high rate of response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been observed in certain patients (women, of East Asian ethnicity, with non-smoking history and adenocarcinoma histology) with mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR. Some cases of high-grade neuroendocrine carcinoma of the lung harboring mutations have been sporadically reported. Methods: We describe the case of a 78-year-old woman with large-cell neuroendocrine carcinoma of the lung, with mutation in exon 21 L858R and co-expression of adenocarcinoma markers. Results: A mass (3.0 cm in diameter) was identified in the inferior lobe of the left lung, accompanied by metastases into ipsilateral mediastinal lymph nodes and elevations of serum pro-gastrin-releasing peptide and carcinoembryonic antigen. Initial transbronchial brushing cytology suggested high-grade neuroendocrine carcinoma favoring small-cell carcinoma in poorly smeared and degenerated preparations, and revealed exon 21 L858R mutation. Re-enlargement of the cancer and bone metastases was observed after chemotherapy, and further testing suggested large-cell neuroendocrine carcinoma with immunoreactivity to markers of primary lung adenocarcinoma and L858R mutation. High-grade neuroendocrine carcinoma with mutations in the tyrosine kinase domain of EGFR may be associated with adenocarcinoma, as reviewed from the literature and may also apply to our case. Conclusions: EGFR-TKI could provide better quality of life and survival in patients with advanced or relapsed high-grade neuroendocrine carcinoma with EGFR gene mutations. Further studies in this respect are warranted.

Sign in / Sign up

Export Citation Format

Share Document